Abstract

Value in Health. 2019;22(4):408-415.

DOI of original article: https://doi.org/10.1016/j.jval.2018.11.014

In the introduction section of the article by Garrison et al, the percentages for the 4-year invasive disease-free survival rates for the pertuzumab arm and the control arm were inadvertently transposed. The corrected sentence below reflects the appropriate 4-year invasive disease-free survival values for each arm, as shown in Figure 1A of the pivotal trial publication by von Minckwitz et al:

The 4-year invasive disease-free survival (iDFS) was 92.3% in the pertuzumab arm and 90.6% in the control arm.